Show simple item record

dc.contributor.authorLiu, Shuying
dc.contributor.authorWang, Shixia
dc.contributor.authorLu, Shan
dc.date2022-08-11T08:09:45.000
dc.date.accessioned2022-08-23T16:42:17Z
dc.date.available2022-08-23T16:42:17Z
dc.date.issued2016-04-06
dc.date.submitted2016-10-05
dc.identifier.citationEmerg Microbes Infect. 2016 Apr 6;5:e33. doi: 10.1038/emi.2016.27. <a href="http://dx.doi.org/10.1038/emi.2016.27">Link to article on publisher's site</a>
dc.identifier.issn2222-1751 (Linking)
dc.identifier.doi10.1038/emi.2016.27
dc.identifier.pmid27048742
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40060
dc.description.abstractTo combat the threat of many emerging infectious diseases, DNA immunization offers a unique and powerful approach to the production of high-quality monoclonal antibodies (mAbs) against various pathogens. Compared with traditional protein-based immunization approaches, DNA immunization is efficient for testing novel immunogen designs, does not require the production or purification of proteins from a pathogen or the use of recombinant protein technology and is effective at generating mAbs against conformation-sensitive targets. Although significant progress in the use of DNA immunization to generate mAbs has been made over the last two decades, the literature does not contain an updated summary of this experience. The current review provides a comprehensive analysis of the literature, including our own work, describing the use of DNA immunization to produce highly functional mAbs, in particular, those against emerging infectious diseases. Critical factors such as immunogen design, delivery approach, immunization schedule, use of immune modulators and the role of final boost immunization are discussed in detail.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27048742&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855071/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectImmunoprophylaxis and Therapy
dc.titleDNA immunization as a technology platform for monoclonal antibody induction
dc.typeJournal Article
dc.source.journaltitleEmerging microbes and infections
dc.source.volume5
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=3869&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2864
dc.identifier.contextkey9233084
refterms.dateFOA2022-08-23T16:42:17Z
html.description.abstract<p>To combat the threat of many emerging infectious diseases, DNA immunization offers a unique and powerful approach to the production of high-quality monoclonal antibodies (mAbs) against various pathogens. Compared with traditional protein-based immunization approaches, DNA immunization is efficient for testing novel immunogen designs, does not require the production or purification of proteins from a pathogen or the use of recombinant protein technology and is effective at generating mAbs against conformation-sensitive targets. Although significant progress in the use of DNA immunization to generate mAbs has been made over the last two decades, the literature does not contain an updated summary of this experience. The current review provides a comprehensive analysis of the literature, including our own work, describing the use of DNA immunization to produce highly functional mAbs, in particular, those against emerging infectious diseases. Critical factors such as immunogen design, delivery approach, immunization schedule, use of immune modulators and the role of final boost immunization are discussed in detail.</p>
dc.identifier.submissionpathoapubs/2864
dc.contributor.departmentDepartment of Medicine, Division of General Internal Medicine
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.source.pagese33


Files in this item

Thumbnail
Name:
emi201627a.pdf
Size:
343.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/